For Healthcare Professionals

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031


About the study

Open Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

Male or female study participants with SCD who participated and received study treatment in Study GBT440-031.

Note: Participants in GBT440-031 who discontinued study drug due to an AE, but who remained on study may be eligible for treatment in this study provided the AE does not pose a risk for treatment with voxelotor.

  1. Females of child-bearing potential are required to have a negative urine pregnancy test prior to dosing on Day 1.
  2. Female participants of child-bearing potential must use highly effective methods of contraception to 30 days after the last dose of study drug. Male participants must use barrier methods of contraception to 30 days after the last dose of study drug.
  3. Participant has provided written informed consent or assent (the ICF must be reviewed and signed by each participant; in the case of pediatric participants, both the consent of the participant's legal representative or legal guardian, and the participant's assent must be obtained).


Exclusion Criteria:

  1. Female who is breast-feeding or pregnant.
  2. Participant withdrew consent from Study GBT440-031.
  3. Participant was lost to follow-up from Study GBT440-031.
  4. Participant requiring chronic dialysis.
  5. Any medical, psychological, safety, or behavioral conditions, which, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude informed consent.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Sickle Cell Disease

Age (in years)

12 - 65


Phase 3

Participants needed


Est. Completion Date

Dec 31, 2024

Treatment type



Pfizer identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.